No Data Yet
Gencor Industries reported mixed fiscal 2025 results, showcasing annual profitability growth and a strong balance sheet, but also revealing a quarterly revenue dip and a significantly weakened backlog that suggests future headwinds.
Ligand Pharmaceuticals (LGND) announced robust financial guidance for fiscal year 2026 during its 2025 Analyst Day. The company anticipates substantial growth in revenue and earnings, setting a clear performance benchmark for investors.
The late 2025 financing landscape reveals a selective market, where strong investor appetite for high-growth initial public offerings contrasts with scrutiny over the operational performance of established companies. This environment highlights a focus on future potential over current profitability.
Portfolio
